Cannabics
Pharmaceuticals is engaged in developing sophisticated cannabinoid-based
medicines. Researchers from the cancer research, molecular biology, and
pharmacology fields founded the Bethesda, Maryland-based company in 2012 and,
through a research and development annex in Israel, are cultivating a pipeline
of advanced, cannabinoid-based therapies. In addition, through collaborations
with key medical centers in Europe, Israel, and the United States, Cannabics is
now initiating a series of clinical studies to study the favorable effects of
its products in diverse indications.
Cannabics
develops all of its proprietary technologies in certified laboratories and
licenses the use of these technologies to certified manufacturers and
distributors with the appropriate licenses in their local territories.
Cannabics itself does not manufacture, possess, dispense or distribute
controlled substances.
Cannabics’
laboratories are developing a wide range of standardized, reproducible and easy
to administer solutions around medical cannabis therapies. The company’s
flagship product is Cannabics SR, a sustained-release, medical cannabis capsule
designed as a pain-soothing care treatment for cancer patients. The capsule
provides 10-12 hours of beneficial therapeutic effects and, as a result,
patients need only be dosed once a day. The capsules are also available to
patients in four increasing dosages.
Cannabics
SR capsules contain a pure essence of cannabinoids obtained from carefully
chosen cannabis strains while the excipient, the inactive substance that serves
as the medium for the proprietary sustained-release formulation, is a certified
food-grade ingredient and free of chemical substances and artificial additives.
Cannabics
is committed to researching and developing progressive scientific technologies
in the field of cannabinoid-based therapies. The company’s research is
especially focused on:
• Developing advanced routes for
administering active cannabinoids;
• Identifying the positive therapeutic
effects of various cannabis-based compounds; and
• Developing personalized cannabinoid
therapies as anti-tumor vehicles.
Through
such focused studies, the company’s researchers have gained indispensable
knowledge on the effectiveness of a variety of cannabis strains as therapies
for specific indications. Cannabics’ pharmacology team has also gained valuable
knowledge and expertise on the development of superior delivery systems for
active cannabinoids that offer enhanced treatment options to patients wishing
to use the unique medical properties of the cannabis plant.
For
more information, visit www.cannabics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign
up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please
see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment